Transcription of 平成24年3月期 第1四半期決算 ... - takeda.co.jp
1 24 23 29 4502 (03)3278-2037 23 12 24 23 23 30 (1) 24 357,219 116,210 119,236 75,584 23 354,698 107,261 103,834 64,111 24 51,322 23 9,424 24 23 (2) 24 2,713,566 2,116,407 2, 23 2,786,402 2,136,656 2, 24 2,071,025 23 2,091,589 23 24 24 ( ) 24 23 24 31 ( ) ( ) 720,000 220,000 220,000 140,000 1,450,000 390,000 395,000 250,000 (1) (2) ( ).
2 (3) ( ) . (4) ( ) 24 789,666,095 23 789,666,095 24 264,650 23 295,436 ( ) 24 789,378,045 23 789,379,353 12 23 19 /29( )
3 ( ) 24 ..2 (1) ..2 (2) ..7 (3) ..8 ..9 (1) ..9 (2) ..9 (3) ..9 ..10 (1) ..10 (2) ..12 ..12 ..13 (3) ..14 (4) ..14 (5) ..15 (6) ..15 ..16 (1) ..16 (2) ..16 (3) ..17 (4) ..17 (5) ..18 - 1 - ( ) 24 2010 11-13 Innovation Culture Growth 2009 II
4 100 11-13 28 70 - 2 - ( )
5 24 100 AFSSAPS EMA CHMP FDA EMA CHMP EMA EMA 230 2009 [ ] 2009 2010 2010 OD 2010 11 2011 2011 [ ]
6 2009 2009 2010 XR( ) 2011 [ ] 2010 - 3 - ( ) 24 2011 4-6 25 3,572 100 161 931 64 586 21 321 66 301 22 141 9 89 1.
7 162 33 122 44 78 154 1,192 65 3,572 25 ( ) 1,162 89 ( ) 1,192 154 ( ) 756 115 ( ) - 4 - ( ) 24 115 756 1 14 53 95 75 12 90 110 06 2011 4-6 3,199 18 1,089 77 1,482 78 1,717 60 149 11 40 5 236 4 38 7 3,572 25 1,162 89 18 3,199 77 1,089 78 ( 1.)
8 482 360 14 187 14 167 4 115 7 103 12 60 1,717 - 5 - ( ) 24 11 149 40 236 38 [ ]
9 MLN4924 16 MLN9708 16 TAK-875 71 FDA 2 SYR-322 SYR-322 FDA [ ] - 6 - ( ) 24 [ ] AMG479 LuAA21004 * FDA * SGN-35 brentuximab vedotin ADCETRISTM EMA 16 7,136 728 5.
10 972 526 1,164 202 - 7 - ( ) 24 23 11 24 7,200 2,200 2,200 1,400 14,500 3,900 3,950 2,500 85 120 23 19 11-13 2012
